[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635004":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":15,"responsibleParty":179,"collaborators":7,"id":181,"slug":182,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":183,"sex":189,"minAge":190,"maxAge":7,"enrollmentInfo":191,"targetDuration":7,"studyType":194,"phases":7,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":205,"whyStopped":7,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},"Agnès LE GOUEZ-DIVISIA","CONTACT","1 45 37 42 73","+33","agnes.le-gouez@aphp.fr",[16,30,40,52,65,77,88,100,112,123,134,147,157,167],{"facility":17,"status":7,"city":18,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"CHU Bordeaux","Bordeaux","France","FR",{"type":22,"coordinates":23},"Point",[24,25],-0.58046,44.84124,{"lat":25,"lon":24},[28],{"name":29,"role":11,"phone":7,"phoneExt":7,"email":7},"Aurélie SAN MIGUEL",{"facility":31,"status":7,"city":32,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":33,"geoPoint":37,"contacts":38},"Hôpital Antoine Béclère","Clamart",{"type":22,"coordinates":34},[35,36],2.26692,48.80299,{"lat":36,"lon":35},[39],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},{"facility":41,"status":7,"city":42,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"CHU Clermont-Ferrand","Clermont-Ferrand",{"type":22,"coordinates":44},[45,46],3.08682,45.77969,{"lat":46,"lon":45},[49],{"name":50,"role":11,"phone":7,"phoneExt":7,"email":51},"Martine BONNIN","mbonnin@chu-clermontferrand.fr",{"facility":53,"status":7,"city":54,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Hôpital Bicêtre","Le Kremlin-Bicêtre",{"type":22,"coordinates":56},[57,58],2.36073,48.81471,{"lat":58,"lon":57},[61],{"name":62,"role":11,"phone":63,"phoneExt":13,"email":64},"Marie BRUYERE","1 45 21 34 41","marie.bruyere@aphp.fr",{"facility":66,"status":7,"city":67,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"CHU Lille","Lille",{"type":22,"coordinates":69},[70,71],3.05512,50.63391,{"lat":71,"lon":70},[74],{"name":75,"role":11,"phone":7,"phoneExt":7,"email":76},"Max GONZALEZ-ESTEVEZ","max.gonzalezestevez@chu-lille.fr",{"facility":78,"status":7,"city":79,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CHU Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant","Lyon",{"type":22,"coordinates":81},[82,83],4.84789,45.74906,{"lat":83,"lon":82},[86],{"name":87,"role":11,"phone":7,"phoneExt":7,"email":7},"Lionel BOUVET",{"facility":89,"status":7,"city":90,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"CHU Martinique","Martigues",{"type":22,"coordinates":92},[93,94],5.05526,43.40735,{"lat":94,"lon":93},[97],{"name":98,"role":11,"phone":7,"phoneExt":7,"email":99},"Thibaut RACKELBOOM","thibaut.rackelboom@chu-martinique.fr",{"facility":101,"status":7,"city":102,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"CHRU Nancy","Nancy",{"type":22,"coordinates":104},[105,106],6.18496,48.68439,{"lat":106,"lon":105},[109],{"name":110,"role":11,"phone":7,"phoneExt":7,"email":111},"Florence VIAL","F.VIAL@chru-nancy.fr",{"facility":113,"status":7,"city":114,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"CH Agen-Nerac","Nérac",{"type":22,"coordinates":116},[117,118],0.33844,44.13597,{"lat":118,"lon":117},[121],{"name":122,"role":11,"phone":7,"phoneExt":7,"email":7},"Sandrine PAQUIN",{"facility":124,"status":7,"city":125,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"CHU Carémeau","Nîmes",{"type":22,"coordinates":127},[128,129],4.35788,43.83665,{"lat":129,"lon":128},[132],{"name":133,"role":11,"phone":7,"phoneExt":7,"email":7},"Estelle MORAU",{"facility":135,"status":7,"city":136,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Hôpital Armand-Trousseau","Paris",{"type":22,"coordinates":138},[139,140],2.3488,48.85341,{"lat":140,"lon":139},[143],{"name":144,"role":11,"phone":145,"phoneExt":13,"email":146},"Marie-Pierre BONNET","1 44 73 61 99","marie-pierre.bonnet@aphp.fr",{"facility":148,"status":7,"city":136,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":149,"geoPoint":151,"contacts":152},"Hôpital Cochin Port Royal",{"type":22,"coordinates":150},[139,140],{"lat":140,"lon":139},[153],{"name":154,"role":11,"phone":155,"phoneExt":13,"email":156},"Catherine FISCHER","1 58 41 41 41","catherine.fischer2@aphp.fr",{"facility":158,"status":7,"city":136,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":159,"geoPoint":161,"contacts":162},"Hôpital Necker",{"type":22,"coordinates":160},[139,140],{"lat":140,"lon":139},[163],{"name":164,"role":11,"phone":165,"phoneExt":13,"email":166},"Hawa KEITA-MEYER","1 44 49 41 72","hawa.keita@aphp.fr",{"facility":168,"status":7,"city":169,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"CH de Roubaix","Roubaix",{"type":22,"coordinates":171},[172,173],3.17456,50.69421,{"lat":173,"lon":172},[176],{"name":177,"role":11,"phone":7,"phoneExt":7,"email":178},"Anne-Sophie BAPTISTE","anne-sophie.baptiste@ch-roubaix.fr",{"type":180,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100635004","factors-associated-with-blood-pressure-control-failure-to-intravenous-labetalol-in-severe-preeclampsia-100635004",false,"NCT07547046","Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia","Assessment of the Association Between Predefined Factors and Response or Failure of Blood Pressure Control With Intravenous Labetalol Monotherapy in Severe Preeclampsia: a Multicenter Observational Study","RELAPSE","Inclusion Criteria:\n\n* Adult patient (age ≥ 18 years)\n* Pregnancy ≥ 24 weeks of gestation with one or more viable fetuses and severe preeclampsia requiring intravenous labetalol administration, either as continuous infusion (IVSE) or intravenous bolus titration\n\nExclusion Criteria:\n\n* Contraindication to labetalol (asthma, chronic obstructive pulmonary disease, bradycardia, current or history of intracardiac conduction disorders, or history of hypersensitivity reaction)\n* Intravenous antihypertensive treatment initiated prior to inclusion\n* Patient refusal or objection to the use of her healthcare data for research purposes","FEMALE","18 Years",{"count":192,"type":193},350,"ESTIMATED","OBSERVATIONAL","Severe preeclampsia is a serious pregnancy complication that can lead to severe maternal and fetal outcomes, particularly when blood pressure is not adequately controlled. In France, intravenous labetalol is recommended as the first-line treatment for severe hypertension in preeclampsia. However, in clinical practice, failure to control blood pressure with labetalol is frequently observed, and the factors associated with this lack of response remain poorly understood.\n\nThe RELAPSE study is a prospective, multicenter observational study designed to identify factors associated with failure of blood pressure control with intravenous labetalol monotherapy in patients with severe preeclampsia.\n\nThe main hypothesis is that certain patient characteristics, such as maternal clinical profile, obstetric history, or biological parameters, may be associated with a higher risk of treatment failure. Identifying these factors could help clinicians better anticipate inadequate response to labetalol and adapt treatment strategies more rapidly.\n\nData will be collected from routine clinical care without modifying patient management. Patients will be followed from the initiation of intravenous labetalol until hospital discharge. The study will include approximately 350 patients across multiple centers.\n\nBy improving the understanding of predictors of treatment failure, this study aims to contribute to better management of severe preeclampsia and to reduce maternal and neonatal complications.",[197],"Severe Preeclampsia",[199,200,201,202,203,204],"Severe preeclampsia","hypertensive disorders of pregnancy","pregnancy-related hypertension","maternal morbidity","antihypertensive treatment fa","intravenous labetalol; blood pressure control","NOT_YET_RECRUITING","2026-04-20",{"date":208,"type":209},"2026-04-23","ACTUAL",{"date":211,"type":193},"2026-04-01",{"date":213,"type":193},"2026-05-07",{"name":5,"class":6},14]